Risk factors for herpes zoster in rheumatoid arthritis patients: The role of tumour necrosis factor-α inhibitors

Internal Medicine Journal

Volumn 45, Issue 3, 2015, Pages 310-318

  Segan, J ^a,b   Staples, M P ^a,b   March, L ^c   Lassere, M ^d   Chakravarty, E F ^e   Buchbinder, R ^a,b  

^a MONASH UNIVERSITY   (Australia)

^b CABRINI INSTITUTE   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e OKLAHOMA MEDICAL RESEARCH FOUNDATION   (United States)

Author keywords

Biologic therapy; Cohort study; Herpes zoster; Rheumatoid arthritis; Tumour necrosis factor

Indexed keywords

ADALIMUMAB; CERTOLIZUMAB PEGOL; ETANERCEPT; GOLIMUMAB; INFLIXIMAB; METHOTREXATE; PREDNISOLONE; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; ANTIRHEUMATIC AGENT; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; BACTERIAL SUPERINFECTION; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; HERPES ZOSTER; HUMAN; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; MUSCLE WEAKNESS; POSTHERPETIC NEURALGIA; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK FACTOR; AGED; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; FACTUAL DATABASE; FOLLOW UP; MIDDLE AGED;

ADULT; AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; COHORT STUDIES; DATABASES, FACTUAL; FEMALE; FOLLOW-UP STUDIES; HERPES ZOSTER; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84923822719     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/imj.12679     Document Type: Article

References (32)

1. Nam JL, Winthrop KL, van Vollenhoven RF, Pavelka K, Valesini G, Hensor EMA etal. Current evidence for the management of rheumatoid arthritis with biological disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of RA. Ann Rheum Dis 2010; 69: 976-986.
2. Singh JA, Christensen R, Wells GA, Suarez-Almazor ME, Buchbinder R, Lopez-Olivo MA etal. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst Rev 2009; 4: CD007848.
3. Staples MP, March L, Lassere M, Reid C, Buchbinder R. Health related quality of life and continuation rate on first line biologic therapy among rheumatoid arthritis patients from the Australian Rheumatology Association Database (ARAD). Rheumatology (Oxford) 2011; 50: 166-175.
4. Yazici Y, Shi N, John A. Utilization of biologic agents in rheumatoid arthritis in the United States: analysis of prescribing patterns in 16, 752 newly diagnosed patients and patients new to biologic therapy. Bull NYU Hosp Jt Dis 2008; 66: 77-85.
5. Galloway JB, Hyrich KL, Mercer LK, Dixon WG, Fu B, Ustianowski AP etal. Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly. Rheumatology (Oxford) 2011; 50: 124-131.
6. Listing J, Strangfeld A, Kary S, Rau R, von Hinueber U, Stoyanova-Scholz M etal. Infections in patients with rheumatoid arthritis treated with biologic agents. Arthritis Rheum 2005; 52: 3403-3412.
7. Galloway JB, Mercer LK, Moseley A, Dixon WG, Ustianowski AP, Helbert M etal. Risk of skin and soft tissue infections (including shingles) in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis 2013; 72: 229-234.
8. Sakai R, Komano Y, Tanaka M, Nanki T, Koike R, Nagasawa H etal. Time-dependent increased risk for serious infection from continuous use of tumor necrosis factor antagonists over three years in patients with rheumatoid arthritis. Arthritis Care Res 2012; 64: 1125-1134.
9. Atzeni F, Sarzi-Puttini P, Botsios C, Carletto A, Cipriani P, Favalli EG etal. Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. Autoimmun Rev 2012; 12: 225-229.
10. Donahue JG, Choo PW, Manson JE, Platt R. The incidence of herpes zoster. Arch Intern Med 1995; 155: 1605-1609.
11. Thomas SL, Hall AJ. What does epidemiology tell us about risk factors for herpes zoster? Lancet Infect Dis 2004; 4: 26-33.
12. Gershon AA, Gershon MD, Breuer J, Levin MJ, Oaklander AL, Griffiths PD. Advances in the understanding of the pathogenesis and epidemiology of herpes zoster. J Clin Virol 2010; 48(Suppl 1): S2-7.
13. Gilden D, Mahalingam R, Nagel MA, Pugazhenthi S, Cohrs RJ. Review: the neurobiology of varicella zoster virus infection. Neuropathol Appl Neurobiol 2011; 37: 441-463.
14. McDonald JR, Zeringue AL, Caplan L, Ranganathan P, Xian H, Burroughs TE etal. Herpes zoster risk factors in a national cohort of veterans with rheumatoid arthritis. Clin Infect Dis 2009; 48: 1364-1371.
15. Smitten AL, Choi HK, Hochberg MC, Suissa S, Simon TA, Testa MA etal. The risk of herpes zoster in patients with rheumatoid arthritis in the United States and the United Kingdom. Arthritis Rheum 2007; 57: 1431-1438.
16. Veetil BMA, Myasoedova E, Matteson EL, Gabriel SE, Green AB, Crowson CS. Incidence and time trends of herpes zoster in rheumatoid arthritis: a population-based cohort study. Arthritis Care Res 2013; 65: 854-861.
17. Gupta G, Lautenbach E, Lewis JD. Incidence and risk factors for herpes zoster among patients with inflammatory bowel disease. Clin Gastroenterol Hepatol 2006; 4: 1483-1490.
18. Strangfeld A, Listing J, Herzer P, Liebhaber A, Rockwitz K, Richter C etal. Risk of herpes zoster in patients with rheumatoid arthritis treated with anti-TNF-alpha agents. JAMA 2009; 301: 737-744.
19. Wolfe F, Michaud K, Chakravarty EF. Rates and predictors of herpes zoster in patients with rheumatoid arthritis and non-inflammatory musculoskeletal disorders. Rheumatology (Oxford) 2006; 45: 1370-1375.
20. Serac G, Tubach F, Mariette X, Salmon-Ceron D, Ravaud P, Liote F etal. Risk of herpes zoster in patients receiving anti-TNF-alpha in the prospective French RATIO registry. J Invest Dermatol 2012; 132(3 Pt 1): 726-729.
21. Winthrop KL, Baddley JW, Chen L, Liu L, Grijalva CG, Delzell E etal. Association between the initiation of anti-tumor necrosis factor therapy and the risk of herpes zoster. JAMA 2013; 309: 887-895.
22. Che H, Lukas C, Morel J, Combe B. Risk of herpes/herpes zoster during anti-tumor necrosis factor therapy in patients with rheumatoid arthritis. Systematic review and meta-analysis. Joint Bone Spine 2013; 81: 215-221.
23. Buchbinder R, March L, Lassere M, Briggs AM, Portek I, Reid C etal. Effect of treatment with biological agents for arthritis in Australia: the Australian Rheumatology Association Database. Intern Med J 2007; 37: 591-600.
24. Williams MP, Buchbinder R, March L, Lassere M. The Australian Rheumatology Association Database (ARAD). Semin Arthritis Rheum 2011; 40: e2-3.
25. Wolfe F, Lassere M, van der Heijde D, Stucki G, Suarez-Almazor M, Pincus T etal. Preliminary core set of domains and reporting requirements for longitudinal observational studies in rheumatology. J Rheumatol 1999; 26: 484-489.
26. Bruce B, Fries JF. The Stanford Health Assessment Questionnaire: a review of its history, issues, progress, and documentation. J Rheumatol 2003; 30: 167-178.
27. Gnann JW Jr, Whitley RJ. Clinical practice. Herpes zoster. N Engl J Med 2002; 347: 340-346.
28. Yawn BP, Wollan PC, Kurland M, St Sauver JL, Saddier P. Herpes zoster recurrences more frequent than previously reported. Mayo Clin Proc 2011; 86: 6.
29. Russell M, Schopflocher DP, Svenson L, Virani SN. Secular trends in the epidemiology of shingles in Alberta. Epidemiol Infect 2007; 135: 908-913.
30. Schmader K, George LK, Newton R, Hamilton JD. The accuracy of self-report of herpes zoster. J Clin Epidemiol 1994; 47: 1271-1276.
31. Shafran SD, Tyring SK, Ashton R, Decroix J, Forszpaniak C, Wade A etal. Once, twice, or three times daily famciclovir compared with aciclovir for the oral treatment of herpes zoster in immunocompetent adults: a randomized, multicenter, double-blind clinical trial. J Clin Virol 2004; 29: 248-253.
32. Tyring S, Barbarash RA, Nahlik JE, Cunningham A, Marley J, Heng M etal. Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group. Ann Intern Med 1995; 123: 89-96.